Zenas BioPharma

Today we're thrilled to share transformative news! A license agreement with InnoCare Pharma grants Zenas global development and commercialization rights for a Phase 3 BTK inhibitor for Multiple Sclerosis (MS) and two other assets expected to enter human clinical trials in 2026. Zenas is now proudly advancing two late-stage, potential blockbuster autoimmune disease franchises that strongly position us to improve the lives of patients worldwide. Additionally, today we announced a $120 million private placement financing. Join the Zenas management team for a conference call and webcast today at 8:00 a.m. ET. Register here: https://lnkd.in/eyA4xu-N Read the press release here: https://lnkd.in/e-wJSTnT We are excited for all that’s ahead and thank the Zenas team, InnoCare, new and existing investors, and patients in our clinical trials. #ZenasBio #AutoimmuneDisease #MS #Biotech

We were grateful to sponsor and participate in the IgG4ward! PeachJAM. Our team joined in by doing the “Y” IgG4-RD Warriors’ pose to celebrate the strength and resilience of this community of patients and care partners, and hearing inspiring perspectives. Thanks to IgG4ward! for organizing such a meaningful event and to all who attended to advance awareness, education and support. #IgG4ward #IgG4RD

Today we are thrilled to announce a funding agreement with Royalty Pharma for up to $300 million. Learn more: https://lnkd.in/eitZ2byn With this support, we are exceptionally positioned to execute our late-stage development programs and potential commercialization, taking us closer to making a difference for patients with autoimmune diseases. #ZenasBio #Biotech #AutoimmuneDisease #IgG4RD #MultipleSclerosis #SystemicLupusErythematosus

In September, we’re excited to present at Citi’s 2025 Biopharma Back to School Conference, Cantor Fitzgerald’s Global Healthcare Conference and Morgan Stanley’s 23rd Annual Global Healthcare Conference. Bookmark these details so you can hear about our recent progress and upcoming milestones across our late-stage development programs: https://lnkd.in/e2fXhsjT #ZenasBio #autoimmune #biotech

This morning we shared our second quarter 2025 financial results and corporate updates. We look forward to continuing this exciting momentum as we strive to make a difference for patients. Learn more: https://lnkd.in/gPgsyiUX #ZenasBio #AutoimmuneDisease #IgG4RD #MultipleSclerosis #SystemicLupusErythematosus

Recently, we had the honor of sponsoring the Multiple Sclerosis Association of America (MSAA) Improving Lives Benefit and engaging with the MS patient community. Thanks to our colleagues Cathy Maxwell, MSN, RN, OCN, and Angela Sanchez, RN, DNP, for representing Zenas while celebrating Dr. Barry Singer, MSAA’s Mission Honoree, for his contributions to MS care and research. Today, as we advance an innovative therapeutic option for MS, the Zenas team also recognizes World MS Day, which advocates for the importance of earlier and improved diagnosis. #WorldMSDay #MSAwareness #MultipleSclerosis #AutoImmune #ZenasBio 

Our executive team will be presenting at the Jefferies Global Healthcare Conference next week. Get the details here so you can hear about our recent progress and upcoming milestones: https://lnkd.in/eEYDJhY8 #ZenasBio #autoimmune #biotech

Offering meaningful professional development opportunities is one of the ways we empower our global team. We recently kicked off the Zenas Leadership Development program to foster learning, conversation and growth as we strive to make a difference for patients with autoimmune diseases. Read more about the Zenas experience: https://lnkd.in/eTiV-Txx #ZenasBio #autoimmune

Today we announced our first quarter 2025 financial results and updates across our autoimmune disease clinical pipeline. Learn more about our progress and upcoming milestones: https://lnkd.in/eGJyqrJ4 #ZenasBio #AutoimmuneDisease #IgG4RD #MultipleSclerosis #SystemicLupusErythematosus

We are recognizing Lupus Awareness Month and were honored to hear patient and clinician perspectives at a team gathering. Learn more about systemic lupus erythematosus (SLE) and our Phase 2 SunStone trial: https://lnkd.in/gsyYFn8W #LupusAwarenessMonth #Lupus #SystemicLupusErythematosus